Atea Pharmaceuticals, Inc. (AVIR): Total Assets
$315.22M
As of 2025-12-31
$232.28M
As of 2026-06-30
-22.1%
3-year compound annual growth
-18.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $315.22M | -32.2% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $464.67M | -21.9% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $594.97M | -10.8% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $666.71M | -13.7% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $772.89M | -10.5% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $863.63M | n/m | 2022-02-28, Balance as of period end |
| 2019-12-31 | $22.07M | n/a | 2021-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | 2025-12-31 | $315.22M | -32.2% |
| LB Pharmaceuticals Inc (LBRX) | 2025-12-31 | $312.93M | +833.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $323.15M | +0.4% |
| Omeros Corp (OMER) | 2025-12-31 | $325.63M | +17.5% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $325.95M | +75.5% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $326.80M | -40.3% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $327.65M | -6.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $327.93M | +42.4% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $330.45M | -37.4% |
Compare AVIR, LBRX, ADCT, OMER side by side · Screen every company in Pharmaceutical Preparations ↗